ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Itacitinib Study for Treatment-Naïve Acute Graft-Versus-Host Disease Does Not Meet Primary Endpoint
January 06, 2020Incyte announced the pivotal Phase 3 GRAVITAS-301 study evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease (GVHD) did not meet the primary endpoint of improving overall response rate
Pharma Sources Insight January 2025
